Sign in Subscribe

FDA Rejects UniQure’s Huntington’s Gene Therapy Path – Shares Plunge

UniQure's stock falls sharply in premarket trading after the FDA says early data for AMT-130 isn't enough for approval. The company plans more talks for a Phase III trial on this Huntington's disease treatment.

FDA Rejects UniQure’s Huntington’s Gene Therapy Path – Shares Plunge
Credit: Sipa via AP Images
Already have an account? Sign in.